Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of BMS-962212 in Healthy Subjects
NCT03197779Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2013
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BMS-962212 in thrombosis (5 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Adverse Events (AE) up to 8 days, Serious Adverse Events (SAE) up to 8 days and 13 more. Started Nov 2013; status: completed.
02
Drugs
BMS-962212
03
Conditions
thrombosis
Beyond the preview
Go deeper on NCT03197779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03197779.